

Feto-Maternal Outcome Assessment among Pregnant Women Presenting with Thrombocytopenia: An Observational Study

Priyanka Shahi¹, Ila Priyanka², Geeta Sinha³

¹Senior Resident, Department of Obstetrics and Gynecology, Patna Medical College & Hospital, Patna, Bihar, India

²Assistant professor, Department of Obstetrics and Gynecology, Patna Medical College & Hospital, Patna, Bihar, India.

³Professor and HOD, Department of Obstetrics and Gynecology, Patna Medical College & Hospital, Patna, Bihar, India

Received: 25-12-2022 / Revised: 05-01-2023 / Accepted: 28-01-2023

Corresponding author: Dr. Ila Priyanka

Conflict of interest: Nil

Abstract

Aim: The objective of this study was to study the maternal and fetal outcome among pregnant women presenting with thrombocytopenia.

Methods: The present study was conducted at Department of Obstetrics and Gynecology, Patna Medical College & Hospital, Patna, Bihar, India for the period of one year. Pregnant women with singleton pregnancy with period of gestation 28 week onwards who attended ANC & found to have thrombocytopenia after screening were included. The study was performed after the approval of ethical committee of institute. Sample size 100 patients were included in study.

Results: Mean gestational age was 38.42 ± 1.69 weeks. 15% were < 37 weeks, 70% were in 37 to 40 weeks and 15% were >40 weeks. The mean platelet count was $106907 \pm 30136/ \mu\text{L}$. Majority of women had mild thrombocytopenia (62%). 36% women had moderate thrombocytopenia and only two had severe thrombocytopenia. Association of thrombocytopenia with other medical illness was evaluated in our study. It was found that anemia was associated in 8 women, four women had ITP and hypothyroidism was found in only two women. Rest all women have no diagnosed other medical illness. In our study it was found that PIH was associated with 25% of thrombocytopenic women. Among the 25 women who had PIH, majority of them had gestational hypertension in 60% followed by pre-eclampsia in 24%. Severe pre-eclampsia was noted in two (8%) women. Only two had eclampsia (8%).

Conclusion: Most common cause of thrombocytopenia during pregnancy was gestational thrombocytopenia but other underlying causes must be considered as well. A careful examination and simple laboratory test are needed so that a serious condition that may require specific and urgent management (examples HELLP syndrome, severe pre-eclampsia, TTP, HUS, AFLP) is not missed. Management of pregnant women with platelet disorders requires a multidisciplinary approach.

Keywords: Thrombocytopenia, DIC, Fetal, Maternal.

This is an Open Access article that uses a fund-ing model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Introduction

Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disorder characterized by low platelet counts ($< 150 \times 10^9/L$) and mucocutaneous bleeding. It is relatively common among women of the reproductive age and is the most frequent cause of thrombocytopenia during pregnancy after gestational thrombocytopenia. [1,2] The incidence of ITP in pregnant women in India is approximately 1–2 cases for every 10,000 pregnancy and it accounts for 4–5% of all pregnancy-associated thrombocytopenia. [3,4] Thrombocytopenia in ITP occurs due to the presence of anti-platelet auto-antibodies (IgG antibodies) against platelet membrane glycoproteins. The IgG-coated platelets are cleared from the circulation by the reticuloendothelial system, mainly the spleen producing thrombocytopenia. [2]

The normal range of platelets in non-pregnant women is 150,000–400,000/ μL . Average platelet count in pregnancy is decreased (2,13,000/ μL versus 2,50,000/ μL). Decrease in the platelet count is due to hemodilution, increased platelet consumption, and increased platelet aggregation driven by increased levels of thromboxane A₂. Clinical assessment is most important factor for evaluation of pregnant patient with thrombocytopenia. Proper medical history including current and previous bleeding problem, family history, transfusion history etc should be taken. Examination findings suggestive of thrombocytopenia include the following: petechiae, ecchymosis, nose and gum bleeding, hematuria. [5]

Thrombocytopenia or low blood platelet count is encountered in 7–8% of all pregnancies. But when patient's obstetric and medical condition are excluded, incidence down to 5.1%. Obstetricians diagnose thrombocytopenia by automated complete blood cell counts during routine prenatal screening. It can result from a wide range of conditions, several of them being pregnancy related. [6]

Alloimmune thrombocytopenia represents the most common cause for profound fetal/neonatal thrombocytopenia and intracranial hemorrhage in the infant. Alloimmune thrombocytopenia has no effect on maternal platelet counts. Thrombocytopenia during pregnancy is an underexplored condition in Indian women, so the study was planned to find out the prevalence and causative factors of thrombocytopenia during pregnancy and to review management strategies for the best fetal-maternal outcomes.

The objective of this study was to study the maternal and fetal outcome among pregnant women presenting with thrombocytopenia.

Materials and Methods

The present study was conducted at Department of Obstetrics and Gynecology, Patna Medical College & Hospital, Patna, Bihar, India for the period of one year. Pregnant women with singleton pregnancy with period of gestation 28 weeks onwards who attended ANC & found to have thrombocytopenia after screening were included. The study was performed after the approval of ethical committee of institute. Sample size 100 patients were included in study.

Inclusion criteria

All pregnant women with platelet count less than 1,50,000/ μL who were willing to participate in the study were enrolled for study after period of gestation 28 weeks.

Exclusion criteria

Women with known history of

- Diabetes mellitus
- Collagen disorders
- Tuberculosis
- Epilepsy
- Previous bad obstetric histories
- Pancytopenia
- Bone marrow suppression

Methodology

Antenatal women were enrolled in the study in third trimester. All women had platelet count estimation at the time of enrollment. Platelet count assessment was done through automated blood count analyser with routine antenatal haematological evaluation of the patient.

Baseline investigations like complete haemogram, blood group and Rh typing, O'Sullivan's test, urinalysis, VDRL, HBsAg and HIV serology were carried out in all subjects. Special investigations like Coagulation profile (PT, APTT, FDP and fibrinogen), KFT, LFT were done if clinically indicated. Any other investigation was done as and when required. The detailed work up of all cases was done to ascertain the cause of

thrombocytopenia. All women enrolled were follow up by estimation of platelets count on 7th postpartum.

Statistical analysis

Quantitative data was summarized as mean and standard deviation whereas qualitative data was presented as proportion (%). One-Way ANOVA test ("analysis of variance") and Post hoc Bonferroni test were used for analysis of quantitative data while Chi-square test was used for analysis of qualitative data. P value < 0.05 was taken as significant. Medcalc 16.4 version software was used for all statistical calculation.

Results

Table 1: Distribution of patients according to gestational age and according to platelet count

Gestational Age	N%
>37 weeks	15 (15)
37-40 Week	70 (70)
>40 Week	15 (15)
Mean gestational age	38.42 ± 1.69 weeks
Platelet count	
Mild 100000- 149999	62 (62)
Moderate 50000 -99999	36 (36)
Severe <50000	2 (2)
Mean platelet count	106907±30136/μL

Mean gestational age was 38.42 ± 1.69 weeks. 15% were < 37 weeks, 70% were in 37 to 40 weeks and 15% were >40 weeks. The mean platelet count was 106907±30136/ μL. Majority of women had mild thrombocytopenia (62%). 36% women had moderate thrombocytopenia and only two had severe thrombocytopenia.

Table 2: Distribution of women according to relation with other medical illness and association with PIH

Related medical illness	N%
None	86 (86)
Anemia	8 (8)
ITP	4 (4)
Hypothyroidism	2 (2)
PIH n=25	
Gestational hypertension	15 (60)
Pre-eclampsia	6 (24)
Severe Pre-eclampsia	2 (8)
Eclampsia	2(8)

Association of thrombocytopenia with other medical illness was evaluated in our

study. It was found that anemia was associated in 8 women, four women had

ITP and hypothyroidism was found in only two women. Rest all women have no diagnosed other medical illness. In our study it was found that PIH was associated with 25% of thrombocytopenic women. Among the 25 women who had PIH,

majority of them had gestational hypertension in 60% followed by pre-eclampsia in 24%. Severe pre-eclampsia was noted in two (8%) women. Only two had eclampsia (8%).

Table 3: Distribution of patients according to mode of delivery

Mode of delivery	N%
LSCS	45 (45)
NVD	55 (55)

In our study 55% patients were delivered vaginally and 45% were delivered by LSCS.

Table 4: Neonatal platelet count

Neonatal Thrombocytopenia	N%
Absent	95
Present	5

Out of 100 neonates, 95% (95) had normal platelet count and 5% (5) had thrombocytopenia with platelet count less than 150000/mm³. In our study, almost similar incidence of maternal complication occurred in mild, moderate and severe group of patients. Mean weight of neonates born to the women enrolled in our study was 2.58 kg with SD of 0.49 kg. The maximum weight was 3.5kg and minimum was 1.1kg.

Discussion

Most of the patients with mild thrombocytopenia do not alter the obstetrical management but at times severe thrombocytopenia, in life threatening conditions like HELLP syndrome, poses a great challenge to the treating obstetrician.

In our study, Mean gestational age was 38.42 ± 1.69 weeks which was similar to studies conducted by Chauhan V et al. [7] (38.6 ± 1.34weeks), Sojitra M et al. [8] (38 weeks) and Lin et al. [9] (39 weeks) where as in the study by Bouzari et al. [10] the mean age was 35.83 ± 3.61 weeks which was lower than our study. In our study maximum cases 70% belonged to gestational age 37 to 40 week which was similar to Parnas et al. [11] In our study, 55% women delivered vaginally and 45% had delivered by LSCS which was comparable, to study by Singh J et al. [12]

(vaginally 52% and LSCS 48%), Sojitra M et al. [8] (vaginally 60% and LSCS 40%) and Vyas et al. [13] (vaginally 63% and LSCS 37%) whereas the incidence of LSCS was higher in the studies conducted by pafumi et al. [14] (55%) and Yuce et al. (56%). [15]

In present study mean gestation age at delivery was 38.6±1.34 weeks. In a study conducted by Lin et al and Kasai et al the age was similar to our study 39 weeks and 38 weeks respectively. [9,16] Where as in the study by Bouzari et al the age was 35.83+3.61 weeks which was lower than our study. [10] The mean platelet count in present study was 106907.7±30136.52/μL. In the study conducted by Singh et al mean platelet count was 110320+21345.4/μL which was comparable to our study. [17] Higher mean platelet count was seen in the studies conducted by Pourrat et al (131000/μL) and Jaleel et al (122960+28146.5/μL). [18,19] The mean neonatal platelet count was 175307.7+33834.87/μL. The mean neonatal platelet count was lower than our study in Pourrat et al study (122100/μL). [19] In the study of Yuce et al mean neonatal platelet count was 203000+12101.2/μL which was higher than our study.15 In the present study the association of thrombocytopenia with PIH

was seen in 25% women, which was similar to the studies of Brohi et al (26.70%) [20], Singh et al [17] (24.20%), Vyas et al [13] (22%) Parnas et al [11] (21.11%) and Burrows et al (21%). [21]

The mean weight of neonates born to the women enrolled in our study was 2.58 ± 0.49 kg which was similar to study by Bouzari et al [10] (2.58 ± 0.8 kg) whereas the mean weight was higher in study by Chauhan V et al. [7] (2.80 ± 0.32 kg) and Onisai et al. [22,23] (2.9 ± 0.23 kg) as we included patients with hypertensive disorders (HELLP, preeclampsia, eclampsia, gestational hypertension and superimposed preeclampsia). In our study, out of 100 neonates, 95% (95) had normal platelet count and 5% (5) had thrombocytopenia with platelet count less than 150000/mm³ which is comparable to study reported by Chauhan V et al. [7] in which incidence of neonatal thrombocytopenia was 3.10%. In the study by Singh et al. incidence was 1.09% which lower than our study. [12]

Conclusion

Present study concluded that most common cause of thrombocytopenia during pregnancy was gestational thrombocytopenia but other underlying causes must be considered as well. A detailed history and physical examination is mandatory to rule out most other causes. A thorough study of CBC and smear should be done to rule out pancytopenia and platelet clumping associated with pseudo thrombocytopenia. Previous history of thrombocytopenia should rise the doubt of ITP. A careful examination and simple laboratory test are needed so that a serious condition that may require specific and urgent management (examples HELLP syndrome, severe preeclampsia, TTP, HUS, and acute fatty liver of pregnancy) is not missed. Monitoring of platelet count of mother should be a routine at antenatal visits for timely diagnosis and to achieve favorable obstetric outcome in all types of

thrombocytopenia. Management of pregnant women with platelet disorders requires a multidisciplinary approach and accurate etiological diagnosis is essential for optimal therapeutic management.

References

1. Gernsheimer T, McCrae KR. Immune thrombocytopenic purpura in pregnancy. Current opinion in hematology. 2007 Sep 1;14(5):574-80.
2. Gill KK, Kelton JG. Management of idiopathic thrombocytopenic purpura in pregnancy. In Seminars in hematology. WB Saunders. 2000 Jul 1;37(3): 275-289.
3. ITP A. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol. 2003;120(1):574-96.
4. Nisha S, Amita D, Uma S, Tripathi AK, Pushplata S. Prevalence and characterization of thrombocytopenia in pregnancy in Indian women. Indian Journal of Hematology and Blood Transfusion. 2012 Jun;28(2):77-81.
5. Kumari R. Maternal and fetal outcome among pregnant women presenting with thrombocytopenia.
6. Kadir RA, McLintock C. Thrombocytopenia and disorders of platelet function in pregnancy. In Seminars in thrombosis and hemostasis. Thieme Medical Publishers. 2011 Sep;37(6): 640-652.
7. Chauhan V, Gupta A, Mahajan N, Vij A, Kumar R, Chadda A. Maternal and fetal outcome among pregnant women presenting with thrombocytopenia. Int J Reprod Contracept Obstet Gynecol. 2016 Aug 1;5(8):2736-43.
8. Sojitra M, Shah SR, Mehta AV, Panchal PP, Bhankhar R. Maternal outcome in pregnancy with thrombocytopenia. International Journal of Reproduction, Contraception, Obstetrics and Gynecology. 2020 Jul 1;9(7):2895-900.

9. Lin YH, Lo LM, Hsieh CC, Chiu TH, Hsieh TT, Hung TH. Perinatal outcome in normal pregnant women with incidental thrombocytopenia at delivery. *Taiwan J Obstet. Gynecol.* 2013;52(3):347-50.
10. Bouzari Z, Firoozabadi S, Hasannasab B, Emamimeybodi S, Golsorkhtabar-Amiri M. Maternal and neonatal outcomes in HELLP syndrome, partial HELLP syndrome and severe preeclampsia: eleven years' experience of an obstetric center in the North of Iran. *World Applied Sciences Journal.* 2013; 26(11):1459-63.
11. Parnas M, Sheiner E, Shoham-Vardi I, Burstein E, Yermiahu T, Levi I, et al. Moderate to severe thrombocytopenia during pregnancy. *Eur J Obstet Gynecol Reprod Biol.* 2006;128(1-2):163-8.
12. Singh J, Kumari K, Verma V. Study of thrombocytopenia in pregnancy: clinical presentation and outcome at tertiary care rural institute. *Int J Reprod Contracept Obstet Gynecol.* 2020; 9:1622-6.
13. Vyas R, Shah S, Yadav P, Patel U. Comparative study of mild versus moderate to severe thrombocytopenia in third trimester of pregnancy in a tertiary care hospital. *NHL Journal of Medical Sciences.* 2014;3(1):8-11.
14. Pafumi C, Valenti O, Giuffrida L, Colletta G. Gestational thrombocytopenia: does it cause any maternal and /or perinatal morbidity? *Cukurova Med J.* 2013;38(3):349-57.
15. Yuce T, Acar D, Kalafat E, Alkilic A, Cetindag E, Soylemez F. Thrombocytopenia in pregnancy: do the time of diagnosis and delivery route affect pregnancy outcome in parturients with idiopathic thrombocytopenic purpura? *Int J Hematol.* 2014;100(6):540-4.
16. Kasai J, Aoki S, Kamiya N, Hasegawa Y, Kurasawa K, Takahashi T, Hirahara F. Clinical features of gestational thrombocytopenia difficult to differentiate from immune thrombocytopenia diagnosed during pregnancy. *Journal of Obstetrics and Gynaecology Research.* 2015 Jan; 41(1):44-9.
17. Singh N, Amita D, Uma S, Tripathi AK, Pushplata S. Prevalence and characterization of thrombocytopenia in pregnancy in Indian women. *Indian J Hematol Blood Transfus.* 2012; 28(2):77-81.
18. Jaleel A, Baseer A. Thrombocytopenia in preeclampsia: an earlier detector of HELLP syndrome. *J Pak Med Assoc.* 1997;47(9):230-2.
19. Pourrat O, Valère G, Pierre F. Is incidental gestational thrombocytopenia really always safe for the neonate? *J Obstet Gynaecol.* 2014;34(6):499-500.
20. Brohi ZP, Perveen U, Sadaf A. Thrombocytopenia in pregnancy: an observational study. *Pak J Med.* 2013; 52(3):67-70.
21. Burrows RF, Kelton JG. Thrombocytopenia at delivery: a prospective survey of 6715 deliveries. *Am J Obstet Gynecol.* 1990; 162(3): 731-4.
22. Onisai M, Vladareanu AM, Delcea C, Ciorascu M, Bumbea H, Nicolescu A. Perinatal outcome for pregnancies complicated with thrombocytopenia. *J Matern Fetal Neonatal Med.* 2012; 25(9):1622-6.
23. Ortiz C. T. N., García J. S. R., Rodriguez A. C. E., Gonzalez A. M. Q., Arias E. A. P., Mansilla M. C. N., Valenzuela M. D., & Espitia M. M. B. Auricular L Graft as a Method of Extension of the Nasal Septum. *Journal of Medical Research and Health Sciences.* 2022; 5(4): 1955–1959.